

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/25/2015
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Autoimmune Neurologic Disease Reflexive Panel, CSF

ARUP test code 3002887

N-methyl-D-Aspartate Receptor Ab, CSF

1:10 * (Ref Interval: < 1:1)

Antibodies to NMDA were detected; titer was performed at an additional charge.

INTERPRETIVE INFORMATION: N-methyl-D-Aspartate Receptor Ab, CSF

Anti-NMDA receptor IgG antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

PCCA Detected * (Ref Interval: None Detected)

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

INTERPRETIVE INFORMATION: Paraneoplastic Abs (PCCA/ANNA) IgG, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

AMPA Receptor Ab IgG Screen, CSF

Detected * (Ref Interval: < 1:1)

AMPA Antibody, IgG is detected. Titer results to follow.

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG Screen, CSF

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes AMPAR transfected cell lines for the detection and semi-quantification of AMPAR IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

GABA-B Receptor Ab IgG Screen, CSF

Detected * (Ref Interval: < 1:1)

GABA-BR Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: GABA Receptor Ab IgG Screen, CSF

Gamma-amino butyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semi-quantification of GABA-BR IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

CASPR2 Ab IgG Screen by IFA, CSF

Detected * (Ref Interval: < 1:1)

CASPR2 Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: CASPR2 Ab IgG w/Reflex to Titer, CSF

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

LGI1 Ab IgG Screen by IFA, CSF

Detected * (Ref Interval: < 1:1)

H=High, L=Low, *=Abnormal, C=Critical

LGI1 Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: LGI1 Ab IgG w/Reflex to Titer, CSF

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

CV2.1 Ab IgG Screen, CSF

Detected * (Ref Interval: < 1:1)

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

INTERPRETIVE INFORMATION: CV2.1 IgG Ab with Reflex to Titer, CSF
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

SOX1 Antibody, IgG by Immunoblot, CSF

Positive * (Ref Interval: Negative)

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, CSF
SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Voltage-Gated Potassium Channel Ab, CSF

10.0 pmol/L H (Ref Interval: 0.0-1.1)

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Voltage-Gated Potassium Channel (VGKC) Antibody, CSF
Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (LGII) or contactin-associated protein-2 (CASPR2) instead of potassium channel antigens. A substantial number of VGKC-antibody positive cases are negative for LGII and CASPR2 IgG autoantibodies, not all VGKC complex antigens are known. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Glutamic Acid Decarboxylase Antibody CSF

10.0 IU/mL H (Ref Interval: 0.0-5.0)

INTERPRETIVE INFORMATION: Glutamic Acid Decarboxylase Antibody, CSF
A value greater than 5.0 IU/mL is considered positive for glutamic acid decarboxylase antibody (GAD AB CSF).

This assay is intended for the semi-quantitative determination of the GAD Ab in human CSF. Results should be interpreted within the context of clinical symptoms.

See Compliance Statement B: www.aruplab.com/CS

Purkinje Cell Antibody, Titer, CSF (Do NOT give this test code to clients - Panel Component ONLY. Refer to 2010841.)

ARUP test code 2010845

Purkinje Cell Antibody Titer IgG, CSF

1:10 * (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: Purkinje Cell Antibody Titer IgG, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG, CSF (Reflex of 3001257 AMPA CSF - Not orderable by clients)

ARUP test code 3001263

AMPA Receptor Ab IgG Titer, CSF

1:10 * (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: AMPA Receptor Ab IgG Titer, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Gamma Aminobutyric Acid Receptor , Type B (GABA-BR) Antibody Titer, IgG, CSF (Reflex of 3001267 GABA CSF - Not orderable by clients)

ARUP test code 3001273

GABA-B Receptor Ab IgG Titer, CSF

1:10 * (Ref Interval: < 1:1)

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: GABA-B Receptor Ab IgG Titer, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Contactin-Associated Protein-2 Antibody Titer, IgG by IFA, CSF (Reflex of CASPR2GCSF Only - Not Orderable by Clients)

ARUP test code 3001989

CASPR2 Ab IgG Titer by IFA, CSF

1:10 * (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Leucine-Rich, Glioma-Inactivated Protein 1 Antibody Titer, IgG by IFA, CSF (Reflex for LGI1 IGG CSF Only - Not Orderable by Clients)

ARUP test code 3001994

LGI1 Ab IgG Titer by IFA, CSF

1:10 * (Ref Interval: < 1:1)

INTERPRETIVE INFORMATION: LGI1 Ab Titer IgG by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

CV2.1 Antibody Titer IgG, CSF (Reflex for 3002257 CV2.1 CSF - Not orderable by clients)

ARUP test code 3002258

CV2.1 Antibody IgG Titer by IFA, CSF

1:10 * (Ref Interval: < 1.1)

INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Titer by IFA, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS.

Neuronal Nuclear Antibodies (Hu, Ri, Yo) IgG by Immunoblot, CSF

ARUP test code 2010847

Neuronal Nuclear Ab (Hu) IgG, IB, CSF

Positive * (Ref Interval: Negative)

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Neuronal Nuclear Abs IgG Immunoblot, CSF
This test detects IgG antineuronal antibodies to Hu, Ri, and Yo antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Neuronal Nuclear Ab (Ri) IgG, IB, CSF

Positive * (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

Neuronal Nuclear Ab (Yo) IgG, IB, CSF

Positive * (Ref Interval: Negative)

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, CSF

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
N-methyl-D-Aspartate Receptor Ab, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Purkinje Cell Antibody Titer IgG, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG Screen, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
AMPA Receptor Ab IgG Titer, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-B Receptor Ab IgG Screen, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
GABA-B Receptor Ab IgG Titer, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG Screen by IFA, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG Titer by IFA, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG Screen by IFA, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG Titer by IFA, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Ab IgG Screen, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CV2.1 Antibody IgG Titer by IFA, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SOX1 Antibody, IgG by Immunoblot, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Hu) IgG, IB, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Ri) IgG, IB, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Neuronal Nuclear Ab (Yo) IgG, IB, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Voltage-Gated Potassium Channel Ab, CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glutamic Acid Decarboxylase Antibody CSF	20-237-102113	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 20-237-102113
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 7 of 7 | Printed: 10/12/2020 2:12:56 PM
4848